



# Info day – Tout savoir sur IHI et le prochain appel à propositions (Call 13)

17.06.2026 • Magali Pointot et Nathalie Seigneuret • Online



# Outline of the presentation

- IHI in a nutshell
- Future funding opportunities: introducing IHI Call 13
- Two-stage calls: how does it work



# IHI in a nutshell



# Bold collaborations, transforming health

Who?

IHI is a cross-sector  
EU public-private  
partnership



What?

We create bold  
collaborations – excellent  
health research and  
innovation projects that  
bring together the best  
minds



Why?

Our ultimate goal is to  
transform health across  
the entire spectrum of  
care, especially in areas  
of unmet need






# We are a public-private partnership...

The partners contribute equally to our €2.4 billion budget

## Public

**EU**  
(Horizon Europe)

Funds go to: research orgs, SMEs, patients, healthcare, regulators...



## Industry members

In-kind or financial contribution



## Contributing partners


In-kind or financial contribution

## Private





# ... and so are our projects ...



## Collaboration is part of our DNA



# ... addressing two interlinked challenges


## Challenges that are making it harder for healthcare systems to safeguard the health and wellbeing of their citizens

- Ageing populations, rising burden of disease and emerging health threats, paired with shrinking workforces








## Challenges that are putting a brake on Europe's competitiveness

- Translating results into health solutions remains difficult
- Europe is falling behind as an attractive place for clinical trials
- The vast potential offered by Europe's health data is under-tapped
- The regulatory environment is slow and complex

# A growing IHI community



(IHI grant agreements from Call 1 to 7)



# The IHI portfolio


- Brain
- Healthcare optimisation
- Oncology/Cancer
- 3Rs & Sustainability
- Cardio-metabolic
- Data / AI
- Regulatory
- Chronic Disease
- Communicable diseases

SO1 – Understand Disease | SO2 – Integrated Solution | SO3 – Patient-Centricity | SO4 – Digital Health & AI | SO5 – Value Assessment


(IHI grant agreements from Call 1 to 9)




# What are our projects delivering?




Better understanding of the causes of disease  
– so that we can improve prevention, diagnosis and treatment




Resources and networks to make clinical trials work better for patients and researchers



Techniques to make healthcare more patient-friendly



Markers to help spot when a treatment is working  
– and when it isn't



Guidance on how to make maximum use of health data – while respecting patient privacy





# ● PPPs improving the manufacturing of medical products



IHI and IMI projects are developing new manufacturing techniques, reducing the time that it takes to manufacture critical medical products, providing new tools to make the process more efficient and safer, and securing important supply chains and raw materials.

- EASYGEN is cutting CAR-T cell manufacturing time from 6 weeks to 24 hours
- Thera4Care is improving Europe's supply chain for raw materials needed for theranostics
- Inno4Vac has developed a computer model which can predict the ingredients best suited for vaccine production
- iConsensus produced a series of miniaturised tools to ensure consistent conditions in bioreactors



Partnership  
impact

# Participation of French entities across the programmes (from IMI1 to IHI Call 9)

## Signed grant agreements

	Participations	Participants	EU Contribution	Total In-kind Contribution
IHI	128	74	37,264,272	45,350,811
IMI1	197	90	135,815,062	85,099,733
IMI2	332	131	134,308,087	97,057,514
<b>Grand Total</b>	<b>657</b>	<b>224</b>	<b>307,387,421</b>	<b>227,508,059</b>

## Success rate

IHI	32.1%
IMI1	26.9%
IMI2	30.1%

## Most active participants

SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT  
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE  
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS  
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER  
INSTITUT DE RECHERCHES SERVIER  
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS  
SANOFI R&D VACCINS  
COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES  
INSTITUT PASTEUR  
UNIVERSITE D'AIX MARSEILLE



**Future IHI funding  
opportunities:  
Introducing Call13**



# IHI call 13

Topics under consideration, planned to be launch in summer 2026:

1. A network to boost the new wave of European innovations in healthcare
2. An AI foundation toxicology model and framework to support waiving a second species in drug safety studies
3. Decode the immuno-science of age-related immune-mediated diseases



Read the draft  
topic texts



Unless stated otherwise, all information regarding future IHI call topics is indicative and subject to change. Final information about future IHI calls is communicated after approval by the IHI Governing Board.

# Information on future call topics



Apply for funding

Shape our future research Projects and results Resources for projects News & events About IHI

Home > [Apply For Funding](#) > Future Opportunities

## Future opportunities

Learn about the topics that are in the pipeline for future calls for proposals.



### Learn about our future calls for proposals

We publish information on future call topics a few months ahead of the official call launch. We do this to give you additional time to find or build or prepare a strong proposal. Note that while topics are still under development, the texts may change considerably between the drafts published in this version, and you should always check the final topic texts once they are approved by the IHI Governing Board.

#### IHI call 13 - updated draft topics of 9 June

The following topics are under consideration for inclusion in IHI call 13, which we plan to launch in summer 2026.

- [A network to boost the next wave of European innovations in healthcare](#)
- [An AI foundation toxicology model and framework to support waiving a second species in drug safety studies](#)
- [Decode the immuno-science of age-related immune-mediated diseases](#)

After the project launch



Apply for funding

Shape our future research

Home > [Apply For Funding](#) > Open Calls

## Open calls

Check out our calls that are open for full proposals (single-stage) or short proposals (two-stage).



Under consultation



# Topic 1: A network to boost the next wave of European innovations in healthcare

## Challenge

- Fragmented EU incubator landscape limits scale-up opportunities (financial, expertise, etc.)
- ‘Valley of death’ often encountered by EU start-ups (innovations fail to become marketable products & companies struggle to scale)
- Insufficient regulatory navigation for early-stage companies

## Research hypothesis

- Coordination and networking of EU public & private incubators can reduce fragmentation
- Providing start-ups with early, industry-informed insights will derisk development/accelerate time to market
- Structured regulatory mentoring can improve readiness
- Funding start-ups to strengthen EU retention of innovation



# A network to boost the next wave of European innovations in healthcare

## Overall objective

Create a Network of European HealthCare Incubators which will deliver a structured support framework to enable more effective progression of outputs of early-stage healthcare companies toward deployable innovations in the healthcare ecosystem.

## Expected outcomes

- Sustainable European HealthCare Incubator Network
- Programme for de-risking pipelines & mentoring high potential start-ups
- Agile framework for funding promising start-ups
- Access to high-quality services and infrastructures
- Framework of collaboration with other relevant funding & innovation programmes
- ‘Industry quality seal’ marking Industry-validated promising start-ups
- Opportunities for strategic partnerships
- Portfolio of early-stage companies with improved business, market and technological readiness



# A network to boost the next wave of European innovations in healthcare

## Strategic impacts

- Alignment with the Life Sciences Strategy and Biotech Act objectives
- Strengthening Europe's innovation pipeline and scale-up capability in life sciences

## Indicative budget

- Max. IHI JU financial contribution: EUR 35 000 000\*
- In-kind contribution from industry: EUR 10 696 000\*
- In-kind contribution from contributing partners: EUR 4 328 750\*

*\*The amounts are indicative and subject to change, pending approval by the IHI Governing Board.*



# Topic 2 - An AI foundation toxicology model and framework to support waiving a second species in drug safety studies

## Challenge

- Second-species chronic toxicity studies required before first-in-human studies are costly and variably predictive
- Growing policy pressure to reduce animal testing responsibly
- No harmonised probabilistic framework for waiver decisions currently

## Research hypothesis

- AI models can estimate when second-species studies add limited value
- Federated historical datasets can improve predictive modelling
- Structured weight-of-evidence frameworks can support regulatory confidence



# An AI foundation toxicology model and framework to support waiving a second species in drug safety studies

## Overall objective

Address and standardise the waiver process for second species chronic and sub-chronic small molecule general toxicology studies by developing a transparent, AI-driven Foundation Toxicology Model. The main context of use of the model is to predict if testing in a 2nd species will provide additional safety-relevant information.

## Expected outcomes

- Validated AI Foundation Toxicology Model
- Standardised, transparent weight-of-evidence framework
- Functional tools, templates, and training materials that support the real-world implementation
- Enhanced industry and regulator stakeholder confidence in second species waiver applications



# An AI foundation toxicology model and framework to support waiving a second species in drug safety studies

## Strategic impacts

- Avoiding unnecessary animal studies (second species) & contribution to the 3Rs principle
- EU toxicology platform development

## Indicative budget

- Max. IHI JU financial contribution: EUR 9 000 000\*
- In-kind contribution from industry: EUR 7 300 000\*
- In-kind contribution from contributing partners: EUR 100 000\*

*\*The amounts are indicative and subject to change, pending approval by the IHI Governing Board.*



# Topic 3: Decode the immuno-science of age-related immune-mediated diseases

## Challenge

- Elderly-onset immune diseases are insufficiently characterised including treatment strategies
- Growing burden of multimorbidity in ageing populations
- Limited understanding of interplay between chronic inflammatory diseases and ageing

## Research hypothesis

- Elderly-onset diseases are a different disease with distinct molecular signatures and therapeutic needs
- Common immunosenescence pathways exist across multiple elderly-onset diseases
- Multi-omics integration can enable precision stratification
- Digital biomarkers can support regulatory-relevant endpoints



# Decode the immuno-science of age-related immune-mediated diseases

## Overall objective

Understanding molecular & clinical differences between younger adult-onset and elderly onset diseases:

focus on immune-mediated diseases with a peak of onset in elderly patients, covering gastroenterological diseases, respiratory diseases and rheumatoid diseases:

## Expected outcomes

- Understanding of potential causal links between chronic inflammatory diseases & biological ageing
- Early detection strategies & new diagnostic approaches to differentiate disease onset in elderly vs younger adults
- Repurposing/development of therapies for ageing populations
- Establishment of collaborative approaches for use of biobanks across age-ranges
- Insights into treatment response
- Establishment of regulatory pathways for novel intervention strategies and biomarkers

Unless stated otherwise, all information regarding future IHI call topics is indicative and subject to change. Final information about future IHI calls is communicated after approval by the IHI Governing Board.



# Decode the immuno-science of age-related immune-mediated diseases

## Strategic impacts

- Strengthening Europe's scientific capability in ageing and precision immunology
- Contribution to healthier ageing strategies

## Indicative budget


- Max. IHI JU financial contribution: EUR 9 200 000\*
- In-kind contribution from industry: EUR 9 200 000\*

*\*The amounts are indicative and subject to change, pending approval by the IHI Governing Board.*



# 2-stage calls: How does it work

# How do two-stage calls work?





# Proposal Documents


- The proposal is divided into several documents:
- **‘Part A’** – Administrative details, including
  - Indicative Requested Budget
  - Participants
- **‘Part B’** – The proposal, divided into 3 sections:
  - Excellence
  - Impact
  - Implementation
- **Other Annexes**
  - Type of participant (compulsory)

Task Details	
<b>Task</b>	Write IER
<b>Acronym</b>	Acronym
<b>Proposal</b>	123456
<b>Documents</b>	Part A
	Part B
	Other Annexes

[https://www.ihl.europa.eu/sites/default/files/IHI\\_Proposal\\_template\\_RIA\\_SP\\_PartB.pdf](https://www.ihl.europa.eu/sites/default/files/IHI_Proposal_template_RIA_SP_PartB.pdf)



# Evaluation criteria - Excellence

- 
- **Clarity and pertinence of the project's objectives**, and the extent to which the proposed work is **ambitious**, and goes **beyond the state-of-the-art**.
  - **Soundness of the proposed methodology**



# Evaluation criteria - Impact



- Credibility of the **pathways** to achieve the expected **outcomes and impacts** specified in the work programme, and the likely scale and significance of the contributions due to the project.



# Evaluation criteria – Quality and efficiency of the implementation

- **Quality and effectiveness of the outline of the work plan**
- **Capacity of each participant**, and extent to which the consortium as a whole **brings together the necessary expertise**



# Important consideration

- Remember: the pre-identified industry consortium and contributing partner(s) if any listed in the call topic text will join at stage 2 the first-ranked applicant consortium.
- Applicants should therefore already consider the expected contributions from the pre-identified industry consortium and contributing partner(s) in their proposals in order to successfully enable a public-private partnership.



# Points to remember

- Read all the call-relevant material: [www.ihl.europa.eu](http://www.ihl.europa.eu)
- We expect strong competition: high quality of proposal is a must.
- Ensure that all information is explicitly described in order to allow the expert-evaluators to assess against the evaluation sub-criteria. **Respect the page limit**
- Use the **proposal structure / template**



# ● Sign up for the IHI Call Days for call 13

Online info sessions on all topics plus IHI rules & procedures

## **Decode the immuno-science of age-related immune mediated diseases**

- Wednesday 24 June | 10:30-12:00

## **IHI European HealthCare Incubator Network**

- Monday 29 June | 14:30-16:00

## **Rules and procedures for two-stage calls**

- Tuesday 30 June | 10:30-12:00

## **An AI foundation toxicology model and framework to support waiving a second species in drug safety studies**

- Tuesday 30 June | 14:00-15:30

*\* all times are CEST (Brussels time)*



**Register here**





# Your contact point



**At the IHI Programme Office**



General queries:  
[applicants@ihi.europa.eu](mailto:applicants@ihi.europa.eu)



# Stay in touch



Visit us

[www.ihieurope.eu](http://www.ihieurope.eu)




Write to us

[infodesk@ihieurope.eu](mailto:infodesk@ihieurope.eu)



Sign up  
for our newsletter



## Connect with us



LinkedIn

Innovative Health  
Initiative (IHI)



Bluesky

[@ihieurope.bsky.social](https://bsky.app/profile/ihieurope.bsky.social)



Mastodon

[@IHIEurope@mastodon.social](https://mastodon.social/@IHIEurope)



Thank you for your attention



**innovative  
health  
initiative**



# IHI Call 13: perspective de l'industrie

Nicolas Creff, Associate Director Research Partnerships, EFPIA

Sophie Koettlitz, Senior Expert Research & Innovation, MedTEch Europe

*17 juin 2026*



## Premises:

PPPs are composed of stakeholders, who work together collaboratively, rather than 'outsource' or 'buy in' expertise.

PPPs are an ecosystem. In that ecosystem or 'community of brains', every partner plays a role, and companies, through their in-kind and/or in cash contributions, bring an intrinsic value.

Partnership range from one to one collaborations to large consortia and everything in between

# IHI objectives



## IHI general objectives are to:

- turn health research and innovation into **real benefits for patients and society**;
- deliver safe, effective health innovations that **cover the entire spectrum of care** – from prevention to diagnosis and treatment – particularly in areas where there is an unmet public health need;
- make Europe's health industries globally **competitive**

See <https://www.ih.europa.eu/about-ih/mission-and-objectives>

# Innovative Medicines Initiative and Innovative Health Initiative structuring impact

## Research effectiveness

- Industrial and regulatory grade research infrastructure (e.g. compound libraries, biobanks, CT networks, data hubs)
- Patient engagement toolkit (from methodology to practice)


## Unmet medical needs

- New areas of research enabled or derisked (e.g. autism, rare diseases, novel vaccine development)
- Medicines and vaccines delivered (e.g. Ebola, AMR)
- Integrated care solutions (e.g. cardiovascular to reduce morbidity by 30%)

## The regulatory framework

- Regulatory sandboxes
- Standardised drug development tools validated by regulators (e.g. biomarkers, endpoints)
- Greening (e.g. green chemistry, environmental risk assessment)
- Safety and 3Rs (e.g. pharmacovigilance)

# IHI: A public-private partnership




## Collaboration extends to:

- Programming
- Financing
- Public and private partners collaborating in individual projects

## EUR 2,4 billion total budget:

- 50% EU cash
- 50% industry in kind

# Who are the healthcare industries in IHI?

Trade Association	Represents	Mission/Vision
<a href="#">EFPIA</a> 	Pharmaceutical industry	To create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy.
<a href="#">COCIR</a> 	Medical imaging, radiotherapy, health ICT and electromedical industries	Our industry delivers innovative, data-driven, safe and efficient diagnostic imaging, radiotherapy and digital health solutions for personalized and sustainable care that benefits patients, health professionals and healthcare system.
<a href="#">MedTech Europe</a> 	Medical Technology industry	Make innovative medical technology available to more people, while helping healthcare systems move towards a more sustainable path.
<a href="#">Vaccines Europe</a> 	Vaccine industry	To support broad access to immunisation, enabling better protection of the health of individuals and the wider community throughout life, with both existing vaccines and those in development.
<a href="#">EuropaBio</a> 	Biotech industry	Committed to the socially responsible use of biotechnology to improve quality of life, to prevent, diagnose, treat and cure diseases, to improve the quality and quantity of food and feedstuffs and to move towards a biobased and zero-waste economy.

## EFPIA's perspective on Call 13



### **On call 13, please note that:**

- Industry consortia are led by EFPIA companies (Novo, Pfizer, Sanofi)
- Committed organisations include: EFPIA companies and Contributing Partners

**Therefore, the perspective on Call 13 presented today relates mostly to the pharma industry, and less to the medtech industry.**

# Overall priorities for EFPIA - Competitiveness



## Competitiveness of Europe a key priority for Efpia:

- **Attract:** A Europe that attracts innovators, talent, jobs and investment in research, development and manufacturing
- **Accelerate:** a Europe that accelerates the translation of scientific excellence into healthcare solutions to transform patients' lives
- **Access:** A Europe where Europeans can quickly and equitably access innovative and impactful treatments and vaccines

### *See also :*

- **For EFPIA:** EFPIA positions: [Europe's choice, A Strategy for European Life Sciences](#),
- **IHI:** IHI Annual Work Programmes, IHI Science and Innovation Panel (SIP) reports


# What makes IHI different from regular Horizon Europe calls




- IHI equally associates the **EC and Industry** in selecting the topics... unlike standard Horizon Europe where EC is the sole decider
- Each IHI project **requires 50% of the budget from industry**...unlike standard Horizon where there is no minimum funding from industry
- IHI aims at delivering (direct and concrete) **impact on the healthcare delivery**

# Healthcare stakeholders

## Potential participants to projects



# The complementary value that the industry brings to the table





### **MACUSTAR receives third nod of approval from regulators**

The European Medicines Agency issued a third letter of support for the development of new biomarkers and clinical endpoints for a condition that blurs vision and can lead to blindness.



### **The AUTOPIX project: putting pictures to work for patients**

People with arthritis regularly undergo scans; now a new IHI project will deliver resources to boost the usefulness of the resulting images to both patients and physicians.



### **Italy screens for type 1 diabetes alongside EDENT1FI**

The IHI EDENT1FI project is cooperating with the Italian government as new screening programmes to detect type 1 diabetes in children and teenagers are rolled out.



### **Directing the power of AI towards finding compounds to combat antimicrobial resistance**

The COMBINE project trained an AI model to improve the selection of compounds that can fight multi-drug resistant bacteria – a newly published paper outlines how they did it.



### **PHARMECO plans 'green revolution' in medicines manufacture**

The new IHI project will deliver practical tools and resources to support environmentally-sound decision-making when designing manufacturing processes.



### **New project set to make blood tests simpler and more patient-friendly**


Project-COMFORT aims to make microsampling techniques, which collect minute amounts of blood and can be carried out at home, a standard part of healthcare.

## IHI for companies:

### Value of participating in IHI and defining your role

- IHI is more than a funding or collaborative vehicle
- Strategic commitment and investment in the long term
- Pre-competitive: No product around the corner
- Collaboratively building landscape for long term European research and healthcare
- Share and pool knowledge – be part of long-term shaping of Europe
- Grant funding not driver for industry participation
- Most industrial engagement will be through in-kind contribution
- Things to consider for a role:
  - Within your capacity to provide
  - Part of wider company strategic development
  - Long term, slower moving than 'normal' projects

# Process of an IHI two-stage call



Up-to-date  
information  
always on the  
IHI website

## Future opportunities

Learn about the topics that are in the pipeline for future calls for proposals.



### Learn about our future calls for proposals

We publish information on future call topics a few months ahead of the official call launch. We do this to give you additional time to find or build a consortium and prepare a strong proposal. Note that while topics are still under development, the texts may change considerably between the drafts published here and the final version, and you should always check the final topic texts once they are approved by the IHI Governing Board.

#### IHI call 13 - updated draft topics of 9 June

The following topics are under consideration for inclusion in IHI call 13, which we plan to launch in summer 2026.

- [A network to boost the next wave of European innovations in healthcare](#)
- [An AI foundation toxicology model and framework to support waiving a second species in drug safety studies](#)
- [Decode the immuno-science of age-related immune-mediated diseases](#)

The topics have been sent to the Governing Board for approval. They may therefore change between the versions published here and the call launch, and applicants should check the final, approved topic texts once they are published.

Nevertheless, we strongly encourage anyone interested in these topics to start preparing a proposal and get networking with potential partners.

#### Information on eligibility for funding

Legal entities based in all countries associated to Horizon Europe, including Canada, Switzerland, the UK, and South Korea, will be eligible to receive funding under this call, in line with the normal rules.

#### Join us for the IHI Call Days

Information on the individual topics as well as rules and procedures for two-stage calls will be presented during four webinars from 24-30 June 2026. [Find out more and register.](#)

### Get networking

If you want to apply to take part in a new IHI project, one of your first tasks will be to find or build an applicant consortium, and to do this, you will need to find partners. Tips on finding partners can be found on our find partners page.

[Get tips on finding partners](#) >

### Get informed

If you're considering applying for an IHI call for proposals, we strongly encourage you to read the call documents, and in particular the guide for applicants. We often update the documents so check the call documents page regularly to be sure you have the latest versions.

[Get the call documents](#) >

Draft call texts published early on; e.g. in April 2026 for Call 13 = at least 3 months before official call launch:  
<https://www.ih.europa.eu/apply-funding/future-opportunities>

## Eligibility rules on two-stage calls

**The following entities are not eligible for funding in two-stage calls:**

- For profit entities with more than €500 million annual turnover
- Any entities part of the pre-identified industry consortium (including Contributing Partners)

**Please note EFPIA policy is to not request EU funding in any IHI calls (single or two-stage).**

Only exception: EFPIA SMEs or mid-caps (>500 mln turnover) who are allowed to request funding, however very few cases so far.

# Ongoing projects – Calls already launched

## Avoiding duplications or overlaps with existing projects / closed calls:

### → Please refer to IHI website, projects factsheets on Calls 1-9 (links for each call):

- [Call 1](#): CLAIMS, GUIDE.MRD, IDERHA, IMAGIO, PROMINENT
- [Call 2](#): HEU-EFS, iCARE4CVD
- [Call 3](#): AD-RIDDLE, COMBINE-CT, EDENT1FI, GRIPonMASH, IMPROVE, LIVERAIM, PaLaDin, PREDICTOM, SASICU
- [Call 4](#): ENKORE, NHPig, PharmEco, Project-COMFORT, READI, RealiseD
- [Call 5](#): Accelerate.EU, ILLUMINATE, SEARCHH, SYNTHIA, Thera4Care, UMBRELLA, VICT3R
- [Call 6](#): CAREPATH, GREG
- [Call 7](#): AUTOPIX, BRECISE, EASYGEN, EuroHeartPath, GRACE, INTERCEPT, SHERPA, VIROMARKERS
- [Call 8](#): BRIDGE, UNIFIED, + 2 projects coming soon on osteoarthritis and on prevention of CVDs
- [Call 9](#): ACCESS-AD, AF-B-STEP, COMPASS, END2AMR, EXIT-CVD, GENz-Trials, GUIDE-AI, HospitalAtHome, IMPACT-MED, LIGAND-AI, PATH, PreciseOnco, SEISMIC

### + Launched calls (but projects not started yet):

- [Call 10](#): topics PFAS (PFAROS project), [FORTIFY](#) (EHDS & IP), [MedTechLabel](#)
- [Call 11](#): topics on brain dysfunction, the link between infections and non-communicable diseases, pharmacovigilance, type 1 diabetes, and ambulatory surgical centres (deadline was October 2025)
- [Call 12](#), single-stage, submission deadline April 2026, evaluation ongoing.

Many [IMI2](#) projects still ongoing, see [here](#).

## Online information and guidance

- **IHI Call Days:** presentations and recorded webinars (for call 13: 24-30 June, register [here](#))
- **Call texts:** see [draft Call 13 text](#)
- [Call documents](#) page (including Guide for Applicants)
- **Additional IHI guidance or webinars.** Example: webinar on how to achieve regulatory impact (10 December, details [here](#))
- **Industry model consortium agreement** [here](#)  
(taylor made template, fit for IHI specificities)

FYI – From Call 10 (two-stage): [Health NCP Net practical Q&A](#) listing all the questions asked during the info sessions and linking to the point in the recording where the question is asked and the answer given. Still very useful to prepare for future calls.

## When to communicate with industry

### For 2-stage calls (= Call 13)

- ⊘ \* **you cannot contact industry** before/during the proposal submission because only public partners submit their proposal;
- \* The successful public consortium starts communicating with the predefined industry consortium **only at the second stage for the full proposal**

### For 1-stage calls,

- \* you can start contacting industry **as soon as the draft topic texts are released** on the IHI website (approx 2-3 months before official release)

## Call 13 – Two-stage call

Call launch expected this Summer, however draft texts are available online:

**The following 3 topics are under consideration:**

- [A network to boost the next wave of European innovations in healthcare](#)
- [An AI foundation toxicology model and framework to support waiving a second species in drug safety studies](#)
- [Decode the immuno-science of age-related immune-mediated diseases](#)

More info on IHI 'Future opportunities' page: <https://www.ih.europa.eu/apply-funding/future-opportunities>

### **IMPORTANT:**

- All applications are evaluated by an independent evaluation panel, industry is not involved
- **The evaluators have one reference: the topic text.**

## Call 13: next steps

- **Read topic texts carefully**
- **Network**, start building your applicant consortium or join one
- **Attend the IHI Call 13 webinars:**

**Decode the immuno-science of age-related immune-mediated diseases**

Wednesday 24 June | 10:30-12:00

**A network to boost the next wave of European innovations in healthcare**

Monday 29 June | 14:30-16:00

**Rules and procedures for two-stage calls**

Tuesday 30 June | 10:30-12:00

**An AI foundation toxicology model and framework to support waiving a second species in drug safety studies**

Tuesday 30 June | 14:00-15:30

<https://www.ihi.europa.eu/news-events/events/ihi-call-days-call-13>

- **At national level: contact your IHI SRG member and your Health NCP**

## Further contacts in industry

**COCIR: Enrique Esquivel** [esquivel@cocir.org](mailto:esquivel@cocir.org)

**EFPIA: Nicolas Creff** [nicolas.creff@efpia.eu](mailto:nicolas.creff@efpia.eu)

**EuropaBio: Claire Skentelbery** [C.Skentelbery@europabio.org](mailto:C.Skentelbery@europabio.org)

**MedTech Europe: Jeroen Schuermans** [j.schuermans@medtecheurope.org](mailto:j.schuermans@medtecheurope.org)

**Vaccines Europe: Charlotte Vernhes** [charlotte.vernhes@vaccineseurope.eu](mailto:charlotte.vernhes@vaccineseurope.eu)



**Thank you for you attention**